

REMARKS

I. Status of Claims Pursuant to 37 CFR § 1.173(c)

Claims 1-6 are the pending original claims.

Claims 7-19 are canceled.

Claims 20-21 are pending.

Claims 22-24 are canceled.

Claim 25 is pending.

Claims 26-32 are canceled.

Claim 33 is pending.

Claims 34-37 are canceled.

Claims 38-42 are pending.

Claims 43-58 are canceled.

Claims 59-60 are pending

Claim 61 is canceled.

Claims 62 and 63 are pending.

II. Amendments to Claims and Support Thereof Pursuant to 37 CFR § 1.173(c)

Applicant has made minor amendments to the claim set that was submitted with the Request For Continued Examination on March 12, 2008. As required by 37 CFR § 1.173(c), Applicant provides the following summary of the claim amendments and citations to the specification to support these amendments.

Claim 20 has been amended to replace “at least one access limiting agent” with “reading-inhibit agent”. This change is consistent with the specification as “reading-inhibit agent” is used throughout the specification of the issued patent, for example, at column 2, line 30; column 2, line 58; and column 7, line 45.

Claim 21 has been amended to replace “at least one access limiting agent” with “reading-inhibit agent”. Support for this amendment is provided in the previous paragraph. Claim 21 also has been amended to recite “a dye, a hygroscopic material, a photoreactive material, or a combination thereof.” These examples of reading-inhibit agents were previously in claims 28, 33, and 34, for example, before they were canceled. Support for these examples of reading-

inhibit agents can be found throughout the specification of the issued patent, for example, at column 8, line 54 - column 9, line 48; and column 10, lines 7-40.

Claim 25 has been amended to replace “at least one access limiting agent” with “reading-inhibit agent”. Support for this amendment is provided above. Claim 21 also has been amended to recite “altering the reflectivity of the reflective layer, or physically distorting or altering a portion of the optically-readable medium.” Support for this amendment can be found throughout the specification of the issued patent, for example, at column 8, line 54 - column 9, line 48; and column 3, lines 23-54.

Claims 33, 39, 40, 41, and 42 have been amended to recite “reading-inhibit agent” instead of “at least one access-limiting agent”. Support for this amendment is provided above.

Claim 38 has been amended to recite “short effective life for said optically-readable medium.” Support for this amendment can be found throughout the specification of the issued patent, for example, at column 11, line 64 - column 12, line 5.

Claim 59 has been amended to include the phrase “after removal of an enclosure”. Support for this amendment can be found throughout the specification of the issued patent, for example, at column 2, line 56 - column 3, line 24.

Claim 60 has been amended to include the phrase “included in the optically-readable medium”. Support for this amendment can be found throughout the specification of the issued patent, for example, at column 4, lines 44-50; and column 8, lines 10-16.

Claim 62 has been added. Support for this new claim can be found throughout the specification of the issued patent, for example, at column 8, line 54 - column 9, line 48; and column 10, lines 7-40.

Claim 63 has been added. Support for this new claim can be found throughout the specification of the issued patent, for example, at column 8, line 54 - column 9, line 48; and column 3, lines 23-54.

CONCLUSION

Applicant and the undersigned thank Examiner Davis for considering these amendments and remarks. If the Examiner believes that any issues exist that can be resolved by telephone conference, or that any formalities exist that can be corrected by an Examiner’s Amendment,

please contact the undersigned at (404) 572-3505.

Respectfully submitted,

/ Robert T. Neufeld /

Robert T. Neufeld
Reg. No. 48,394

King & Spalding LLP
34th Floor
1180 Peachtree Street, N.E.
Atlanta, Georgia 30309-3521
404.572.4600